ACHV's cytisinicline shows best-in-class efficacy and safety for smoking cessation. Click here to find out why ACHV stock is ...

A nasal spray for treatment-resistant depression has delivered strong clinical results and rekindled investor hopes.

A panelist discusses how a prospective study demonstrated that twice-daily use of a nasal spray significantly improved tear ...

Probation officials said youths and staff members were hospitalized after a 'suspected overdose and possible exposure to an ...

Positive study results in Phase 2 lead to a green light for the companies’ combination and plans to move their nasal spray ...

BPL-003 showed “robust” efficacy data in treatment-resistant depression, according to analysts from Jefferies, who noted that ...

A new study found that almost all plans in 40 states and Washington, DC covered at least one form of the opioid overdose reversal drug naloxone, although certain restrictions and quantity limits may ...

Xlear, a company based in American Fork, is suing the FTC, fighting regulations restricting its ability to market hygiene ...

Science X is a network of high quality websites with most complete and comprehensive daily coverage of the full sweep of science, technology, and medicine news ...

Zolmitriptan has previously been shown to appear in plasma as early as 5 minutes after administration. [3, 4] The nasal spray also demonstrates a very fast onset of action, with high and sustained ...